Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease

Exp Neurol. 2004 Aug;188(2):491-4. doi: 10.1016/j.expneurol.2004.05.003.


The safety and tolerability of high dosages of coenzyme Q10 were studied in 17 patients with Parkinson's disease (PD) in an open label study. The subjects received an escalating dosage of coenzyme Q10--1200, 1800, 2400, and 3000 mg/day with a stable dosage of vitamin E (alpha-tocopherol) 1200 IU/day. The plasma level of coenzyme Q10 was measured at each dosage. Thirteen of the subjects achieved the maximal dosage, and adverse events were typically considered to be unrelated to coenzyme Q10. The plasma level reached a plateau at the 2400 mg/day dosage and did not increase further at the 3000 mg/day dosage. Our data suggest that in future studies of coenzyme Q10 in PD, a dosage of 2400 mg/day (with vitamin E/alpha-tocopherol 1200 IU/day) is an appropriate highest dosage to be studied.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcium / blood
  • Coenzymes
  • Cognition / drug effects
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Dyspepsia / chemically induced
  • Female
  • Humans
  • Male
  • Middle Aged
  • Motor Activity / drug effects
  • Parkinson Disease / blood
  • Parkinson Disease / drug therapy*
  • Pilot Projects
  • Safety
  • Time Factors
  • Ubiquinone / adverse effects
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / blood
  • Ubiquinone / therapeutic use*
  • Vitamin E / blood
  • Vitamin E / therapeutic use


  • Coenzymes
  • Ubiquinone
  • Vitamin E
  • coenzyme Q10
  • Calcium